As seen inFig

As seen inFig. stability, which may have a bearing on the functions of these keratins. Keywords:Hepatocyte, Intermediate Filaments, Proteasome, Protein Stability, Ubiquitination, Keratin 18, Keratin 8,O-GlcNAc == Introduction == Intermediate filaments form the largest group of cytoskeletal proteins (14), and among them keratins constitute the most diverse family. At least 3537 keratin (K)3polypeptides (K1 to K37) are known until now, which are predominantly expressed in human epithelial tissues. They are further classified as type I (K9 to K28) and type II (K1 to K8 and K71 to K80) (5). These exhibit coordinated expression in specific pairs of type I and type II keratins in various tissues in a development- and differentiation-dependent manner (2,4,68). This feature of keratin expression has been utilized in the development of tissue-specific markers and distinguishes different epithelial cell types. For example, basal epidermal Tenoxicam keratinocytes communicate K5/14, suprabasal keratinocytes in the top layer of pores and skin communicate K1/10, and wound healing epithelial cells communicate K6/16 (5,8,9). Simple epithelial cells like pancreas, liver, and intestinal lining express keratin pair K8/18 along with variable levels of K19, K20, and K7 (10). Keratins, like all other intermediate filament proteins, share a common structure consisting of a central coiled coil, Tenoxicam -helical conserved pole domain that is flanked by non–helical amino-terminal head and carboxyl-terminal tail domains (7,11,12). The head and tail domains of keratins are relatively nonconserved and harbor sites for post-translational modifications like phosphorylation and glycosylation (13). Keratin pair 8/18 and its rules by phosphorylation are the the majority of widely studied. A number of sites of serine phosphorylation have been identified in the head and tail domains of K8 (Ser-23/Ser-73/Ser-431) and K18 (Ser-33/Ser-52) (10,14). Site-specific phosphorylation on K8/18 regulates their association with cellular proteins (1,15), ubiquitination, turnover (16,17), and most importantly their filament assembly Tenoxicam and business (1). It plays a major part in regulating the dynamic exchange of subunits between the soluble keratins present as a minor fraction and the polymerized keratin intermediate filaments (1823). This dynamic reorganization of keratins is essential for progression of cells through mitosis (24) and in enabling them to resist various mechanical (20,21,25) and nonmechanical tensions (26). The hyperphosphorylation of K8/18 is known to correlate with progression of chronic liver disease in individuals (27), suggesting that alterations in filament reorganization because of phosphorylation could impact their cellular functions. K8/18 glycosylation happens as addition of a singleO-linked -N-acetylglucosamine (O-GlcNAc) sugars Tenoxicam moiety. Event ofO-GlcNAc was first explained in 1984 in lymphocytes (28). Since then, this unique Tenoxicam type of glycosylation is usually explained on serine and threonine residues of various classes of nuclear and cytoplasmic proteins that include transcription factors, kinases, phosphatases, metabolic enzymes, proteasome subunits, oncoproteins, tumor suppressors, and cytoskeletal proteins (2931). Accumulating evidence indicates its part in diseases like neurodegeneration, diabetes, and cancer. Like phosphorylation,O-GlcNAc is a dynamic modification with its addition and removal regulated by two enzymes,O-GlcNAc transferase (32,33) andO-GlcNAcase (3436), respectively. Due to its dynamic nature,O-GlcNAc is known to Mouse monoclonal to CD10.COCL reacts with CD10, 100 kDa common acute lymphoblastic leukemia antigen (CALLA), which is expressed on lymphoid precursors, germinal center B cells, and peripheral blood granulocytes. CD10 is a regulator of B cell growth and proliferation. CD10 is used in conjunction with other reagents in the phenotyping of leukemia regulate numerous functions like protein phosphorylation, subcellular localization, protein-protein relationships, gene transcription, and degradation (31). Three sites ofO-GlcNAcylation have been mapped in the head domain name of K18 at Ser-29, Ser-30, and Ser-48 (37). The sites onO-GlcNAcylation on K8 are not yet identified; however, peptide mapping shows.